Eli Lilly said Wednesday that its experimental drug solanezumab failed to improve cognition of patients with mild Alzheimer's disease in a large phase III clinical trial.

If you liked this article you might like

Eli Lilly to Invest $850M in U.S. Capital Projects This Year
Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk
Cramer: 3 Health Care Bill Scenarios, 3 Game Plans
European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details